These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29658563)

  • 1. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
    Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
    Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
    Mortensen ACL; Morin E; Brown CJ; Lane DP; Nestor M
    EJNMMI Res; 2020 Apr; 10(1):38. PubMed ID: 32300907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
    DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
    Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
    Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
    Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
    Maisonial-Besset A; Witkowski T; Navarro-Teulon I; Berthier-Vergnes O; Fois G; Zhu Y; Besse S; Bawa O; Briat A; Quintana M; Pichard A; Bonnet M; Rubinstein E; Pouget JP; Opolon P; Maigne L; Miot-Noirault E; Chezal JM; Boucheix C; Degoul F
    Oncotarget; 2017 Mar; 8(13):22034-22047. PubMed ID: 28423546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice.
    Weng D; Jin X; Qin S; Lan X; Chen C; Sun X; She X; Dong C; An R
    Oncotarget; 2017 Jul; 8(27):44004-44014. PubMed ID: 28430648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
    Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
    J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.